1. Introduction {#sec1}
===============

Meniere\'s disease (MD) is characterized by episodic vertigo, fluctuant hearing loss, tinnitus, and aural fullness. The illness is associated with the formation of endolymph in the inner ear, causing the so-called endolymphatic hydrops that are visible via MRI based on the work of Zou et al. in 2000 ([@bib80], [@bib82]). The mechanism of MD remains largely unknown. However, an immune-inflammatory reaction has been suspected to be involved in the pathological progression; this hypothesis is supported by the works of Brookes in 1986 and Zou et al. in 1992 ([@bib6]; [@bib76]). The endolymphatic sac (ES) plays critical roles in homeostatic and immune regulations in the inner ear. Several members of the solute carrier gene family were upregulated in human ES ([@bib42]). Takahashi & Harris identified T-cells, macrophages, and immunoglobulins throughout the ES ([@bib64]), and molecules, such as Toll-like receptors (TLRs) ([@bib43], [@bib41]), which supports the hypothesis that the ES serves as an innate immune organ in the inner ear. Potent involvement of the ES in amplification of adaptive immune responses has been implicated based on the expression of tumor necrosis factor-α and immune regulatory peptide transforming growth factor-β secondary to cochlear antigen challenge ([@bib54], [@bib55]). The ES is also a target of immune injury that was demonstrated by histology in MD patients ([@bib10]). Furthermore, immunoglobulin depositions (IgA, IgM and IgG) in the ES have been observed in a subpopulation of MD patients ([@bib2]; [@bib60]; [@bib71]). Pro-inflammatory cytokines produced in the ES may diffuse to the cochlea via a mechanism similar to gadolinium movement through the endolymph in MD observed in an MRI study ([@bib32]). Gene mutations have been reported in MD patients ([@bib34], [@bib33]; [@bib51]), but the genetic background of MD patients associated with immune regulation are still lacking in the literature with the exception of reports demonstrating effects of allelic variants in the MICA, TLR10, and NFKB1 genes on hearing loss progression in MD ([@bib7]; [@bib52]).

Favoring the suspected immune-inflammatory mechanism of MD, systemic administration and/or local perfusion of corticosteroids into the middle ear have been adopted as an alternative therapy for intractable MD ([@bib56]). However, systemic administration of steroids had adverse effects, and intratympanic injection of dexamethasone in a group of patients with unilateral MD (Shea\'s stage IV) exhibited no benefit compared with placebo for the treatment of hearing loss and tinnitus ([@bib59]). In 2001, Kitahara et al. reported the beneficial effect of exposing the opened ES to high-dose steroids to treat intractable MD ([@bib24]). However, the hearing results were the same as those with nonsurgical treatments, and the long-term results in the vertigo control were similar to those of standard ES decompression and even sham decompression ([@bib4]; [@bib65]). Recently, Bojrab et al. injected dexamethasone into the intact ES of MD through ES decompression; however, no additional effects were noted compared with ES decompression without injection ([@bib3]).

Regardless of steroid delivery, standard ES decompression, exposure of the opened ES to high concentrations of steroids, and endolymphatic duct blockage may activate endogenous damage-associated molecular patterns in the ES and further induce inflammation in the inner ear ([@bib84]). Dexamethasone injection into the intact ES is actually harmful to the inner ear due vascular leakage and inflammation upon exciting the transient receptor potential vanilloid-4 (TRPV-4) in the sac via an abrupt increase in the static pressure inside the ES ([@bib9]; [@bib37]; [@bib63]). Therefore, I designed a novel therapy by delivering high-dose steroids to the surface of the intact ES and incus in a sustainable manner to treat refractory MD cases. The whole immune genome of the patient who received the novel therapy was sequenced. The results are reported as follows.

2. Case presentation {#sec2}
====================

2.1. Clinical data {#sec2.1}
------------------

A 57-year-old woman complained of episodic vertigo and fluctuant hearing loss, tinnitus, and aural fullness in the right ear with a 2-year duration, and the symptoms were exacerbated for greater than 2 months. Rotational vertigo occurred in early June 2016 and was accompanied by nausea, hearing loss and aural fullness in the right ear. The vertigo is automatically relieved in several hours, and the hearing recovered while the aural fullness resolved. However, high-tone tinnitus appeared in the right ear. The symptom cluster repeated every 3--4 months and had become more frequent in the most recent 2 months, and each episode lasted 5--8 h. Audiogram revealed low-frequency sensorineural hearing loss on 23-12-2016 and flattened mixed hearing loss on 21-5-2018 in the right ear ([Fig. 1](#fig1){ref-type="fig"}). A type As tympanogram appeared in both ears with double peaks in the right ear, and reflexes were induced on both sides ([Fig. 1](#fig1){ref-type="fig"}). Gadolinium-enhanced MRI demonstrated extreme endolymphatic hydrops in the right cochlea and significant endolymphatic hydrops in the right vestibule ([Fig. 2](#fig2){ref-type="fig"}), and the degrees were defined according to previous reports ([@bib46]; [@bib70]). Systemic administration of agents with the intent to improve blood circulation and neural function revealed insignificant effects. The patient visited me on 5-6-2018, and the diagnosis of MD was made according to the diagnostic criteria for MD jointly formulated by the classification committee of the Barany Society in 2015 ([@bib30]) and the editorial board of Chinese Journal of Otorhinolaryngology-Head and Neck Surgery and the Society of Otorhinolaryngology-Head and Neck Surgery of the Chinese Medical Association in 2017 ([@bib11]). The tympanic membranes appeared normal on both sides. Targeted delivery of dexamethasone onto the posterior tympanic medial wall (0.2 ml, 10 mg/ml, twice weekly for a total of 4 procedures) using a soft-tipped microirrigation catheter together with low-frequency vibration at 100 Hz that were delivered to the ipsilateral mastoid process for 30 min were performed (twice weekly for a total of 4 procedures) with a protocol that was modified from a previous report ([@bib78]). In the modified protocol, a tiny penetration was made in the posterior upper quadrant of tympanic membrane adjacent to the pars flaccida, and the plastic catheter was inserted onto the posterior tympanic medial wall through the penetration. Blood was obtained for immune gene sequencing on 3-7-2018. The vertigo attack intensity was reduced but still recurred. More than 10 episodes occurred during July of 2018, and the patient insisted on surgical treatment. She was admitted on 30-7-2018 for high-dose steroid delivery to the surface of the intact ES and incus that was performed on 1-8-2018. The patient had also been diagnosed with hyperthyroidism in 1999 and hypothyroidism in 2016.Fig. 1Previous audiogram measured in other hospitals. Low-frequency hearing loss of the right ear (A) showed partial recovery on the second measurement (B). Type As tympanogram appeared on both ears with double peaks on the right ear (C).Fig. 1Fig. 2Endolymphatic hydrops in both the cochlea and vestibule on the right side demonstrated by gadolinium-enhanced MRI. The images were obtained using 3D inversion-recovery turbo spin echo with real reconstruction sequence 4 h after intravenous injection of double doses of Gd-DTPA at Shanghai ENT hospital. In the right cochlea, marked hydrops was detected based on the bright semicircular appearance of the scala tympani and vestibuli (arrowhead) ([@bib70]); in the vestibule, obvious endolymphatic hydrops was defined by an endolymph/total lymph ratio \> 33% (=43%) (arrow) ([@bib46]). Scale bar = 10.0 mm. L: left; R: right ear.Fig. 2

Autoinflammation was suggested by preoperative blood examinations. Routine blood tests revealed decreased white blood cell count (3.25 × 10^9^/L), neutrophils (1.19 × 10^9^/L, 36.7%) and hematocrit (35%) and increased lymphocytes (49.5%) and mononucleocytes (9.5%). Thrombin time was slightly high (14.5 s). Routine urine tests revealed that red blood cells (25/μl) and cystatin C were elevated (1.39 mg/L). Blood biochemistry demonstrated that albumin/globulin was slightly low (1.44), glucose was high (7.0 mmol/L), low-density lipoprotein was slightly high (3.63 mmol/L), apolipoprotein A1 was low (1.02 g/L), retinol-binding protein was slightly low (23 mg/L), and complement 3 was low (0.76 g/L). Autoantibody spectrum revealed negative results except that anti-β2-glycoprotein 1 antibody was high (31.02 RU/ml) and circulating immunoglobulins were normal. The other blood immunological test revealed that thyroglobulin protein was low (\<0.04 ng/ml), *Treponema pallidum* antibody was positive (chemiluminescence) (the patient denied any associated sexual history), and rheumatoid factor and C-reaction protein were in a normal range.

2.2. Gene sequencing {#sec2.2}
--------------------

All 232 candidate genes involved in immune regulation, which were selected according to Human Phenotype Ontology (<http://human-phenotype-ontology.github.io/>), were sequenced using next generation sequencing, a high-throughput method to foster novel discovery in biomedical research. Gene sequencing was performed using an Illumina HiSeq 2000 Sequencer (Illumina, California, USA) as previously reported ([@bib83]). The data were analyzed using the following program: bwa-0.7.10, samtools-1.0, picard-tools-1.119, bamtools-2.3.0, Genome Analysis TK-3.3.0, Annovar-2014-11-12. REVEL (rare exome variant ensemble learner) software was used to predict the pathogenicity of missense variants on the basis of individual tools ([@bib20]). Mutations were confirmed using Sanger sequencing in both the patient and her daughter.

2.3. Surgery for steroid delivery to the surface of the intact endolymphatic sac and incus {#sec2.3}
------------------------------------------------------------------------------------------

The operation was performed under general anesthesia using facial nerve monitoring, and a strict sterile work environment was guaranteed. The procedure is illustrated in [Fig. 3](#fig3){ref-type="fig"}. A simple mastoidectomy was performed through a retro-auricular incision, and the mastoid cavity was skeletonized by displaying the short process of the incus, superior part of the mastoid segment of the facial nerve canal, sinodural angle, and lateral and posterior semicircular canals. The ES was exposed by drilling the bones in the area between the sigmoid sinus and the inferior margin of the posterior semicircular canal ([Fig. 4](#fig4){ref-type="fig"}A). Gelatin sponge particles with dimensions of 5.0 × 5.0 × 5.0 mm^3^ were immersed in a total of 80 mg methylprednisolone sodium succinate that was suspended in 1 ml saline and placed onto the surface of ES. Then, 2 strips of gelatin sponge with dimensions of 60.0 × 5.0 × 5.0 mm^3^ were immersed in dexamethasone solution (8.3 mg/ml) and bent at 90° in the middle ("L" shape) to serve as guiding device for the steroids. The angular fragment was placed at the sinodural angle. One arm was positioned at the short process of incus, and the other arm was placed over the gelatin sponge particles on the surface of ES ([Fig. 4](#fig4){ref-type="fig"}B). Numerous gelatin sponge particles were immersed in the abovementioned dexamethasone solution (a total of 3.6 ml solution was used), placed around the previous gelatin sponge ([Fig. 4](#fig4){ref-type="fig"}C), and sealed using fibrin glue ([Fig. 4](#fig4){ref-type="fig"}D). The remainder of the mastoid cavity was filled with gelatin sponge pieces containing a mixture of ciprofloxacin hydrochloride ear drops (3 mg/ml) and dexamethasone (5 mg/ml), and the wound was closed with skin sutures.Fig. 3Illustration of the delivery of high-dose steroids onto the surface of the endolymphatic sac (ES) and incus. The surgical landmarks are shown in A. Methylprednisolone sodium succinate-containing gelatin sponge particles (MGSP) were placed onto the surface of the intact ES (B). Dexamethasone-containing gelatin sponge strips (DGSSs) were installed to touch the short process of the incus and MGSP (C). Numerous dexamethasone-containing gelatin sponge particles (DGSP) were placed around DGSSs (D). DGSPs were sealed with fibrin glue (FG). The remainder of the mastoid cavity was filled by ciprofloxacin hydrochloride and dexamethasone-containing gelatin sponge particles (CDGSP).Fig. 3Fig. 4Main steps of the surgery for high-dose steroid delivery to the surface of the intact endolymphatic sac (ES) and incus. A. The ES was exposed. B. Dexamethasone-containing "L"-shaped gelatin sponge strips (GSSs) were placed onto the surface of the short process of incus (1), outer surface of the ES that was covered by methylprednisolone sodium succinate-containing gelatin sponge particles (GSP) (2) and the sinodural angle (3). C. Numerous dexamethasone-containing GSPs were piled around the previous gelatin sponge materials. D. Dexamethasone-containing GSPs were sealed using fibrin glue (FG). LSCC: lateral semicircular canal; PSCC: posterior semicircular canal.Fig. 4

2.4. Inner ear MRI to detect EH {#sec2.4}
-------------------------------

The patient was seen on 30-11-2018 (4 mon post operation) for MRI to detect potent EH. Briefly, 0.1 ml of 20-fold diluted gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) was delivered onto the posterior upper portion of the tympanic medial wall of each ear as previously report ([@bib85]). After each injection, the patient was instructed to lie on the bed in a lateral position with the injected ear upward and turned approximately 30° backward for 15 min. Inner ear MRI was performed 24 h after Gd-DTPA administration using a 3T MR machine (Skyra, Siemens, Munich, Germany) and a 20-channel Tim 4G head/neck coil (Siemens, Munich, Germany). Potent EH was detected using a modified 3D-real inversion recovery (m3D-real IR) based on T2-sampling perfection with application-optimized contrasts using a flip angle evolution (SPACE) sequence. The parameters for SPACE were as followings: TR 4400 ms, TE 544 ms, echo spacing 5.43 ms, allowed delay 30 s, bandwidth 434 Hz/Px, flip angle (FA) 120°, strong fat suppression, FOV 196 \* 84.4 mm, slice thickness 1.0 mm, averages 1.8, slices per slab of either 104, and scanning time 3.4 min. The parameters for m3D-real IR were as followings: TR 16000 ms, TE 663 ms, echo spacing 5.43 ms, inversion time (TI) 2700 ms, FA 180°, strong fat suppression, FOV read 196 \* 165.4 mm, matrix 384\*324, slice thickness 1.0 mm, and averages 2. Slices per slab of either 104 or 60 were selected, which corresponds to scanning time of either 15 min 11 s or 8 min 50 s. Potent EH was judged according to previous reported suggestions by measuring the area using ImageJ (version 1.50i, National Institute of Health, USA) ([@bib46]; [@bib70]).

3. Results {#sec3}
==========

3.1. Candidate gene variants {#sec3.1}
----------------------------

Rare coding heterozygous variants of unknown significance were detected in *PRF1*, *UNC13D*, *SLC29A3*, *ITCH*, and *JAK3* using next generation sequencing and were confirmed in both the patient and her daughter using Sanger sequencing ([Table 1](#tbl1){ref-type="table"}, [Fig. 5](#fig5){ref-type="fig"}). The sequences of variants in *PRF1*, *SLC29A3*, and *ITCH* have not been reported in the literature to date. The REVEL order is as followings: *PRF1* \> *UNC13D* \> *SLC29A3* \> *ITCH* \> *JAK3*.Table 1Candidate gene variants detected the patient and her daughter.Table 1Chr positionGeneExonVariantsStatus1000GgnomAD-exome EASPolyphen2SIFTNotechr10-72358767*PRF1*3c.710C \> A(p.T237N)hetnoneUAD(0.997)D (0.0)novelchr10-73122036*SLC29A3*6c.1099G \> A(p.A367T)hetnone0.000D(0.821)D (0.048)novelchr20-33068519*ITCH*19c.1934A \> G(p.N645S)hetnone0.0000599D(0.911)D (0.028)novelchr19-17943330*JAK3*19c.2678C \> T(p.P893L)hetnone0.0004893D(0.45)D (0.299)Not MD\*chr17-73832723*UNC13D*14c.1228A \> C(p.I410L)het0.00280.01588B(0.021)T (1.0)Not MD\*[^1][^2]Fig. 5Confirmation of gene mutations using Sanger sequencing. The same gene mutations were noted in the patient and her daughter.Fig. 5

3.2. Symptom changes {#sec3.2}
--------------------

The patient had insomnia the first night after operation that was subsequently resolved by taking compound diazepam tablets. The vertigo was fully relieved immediately after operation, and tinnitus and aural fullness resolved 3 w after operation. She had hearing loss on the operated ear that started to improve 2 w after operation. A tuning fork test indicated conductive hearing loss on the operated ear. In 1 mon postoperation, a type B tympanogram was displayed, and an audiogram demonstrated hearing improvement at higher frequencies (2, 4, and 8 kHz) but loss at low frequencies (250 and 500 Hz) for both air and bone conductions. No hearing change was noted on the contralateral side ([Fig. 6](#fig6){ref-type="fig"}). The patient informed me via the internet 2 mon postoperation that her hearing recovered. The audiogram in 2 mon revealed that hearing improved at all frequencies compared with that before operation with an average improvement of 15 dB at 0.5, 1, and 2 kHz. A type As tympanogram with slightly double peaks was detected and was similar to that before operation ([Fig. 7](#fig7){ref-type="fig"}). MRI in 4 mon demonstrated mild vestibular hydrops on both sides and extreme cochlear hydrops on the right side. The endolymphatic sacs were symmetric bilaterally ([Fig. 8](#fig8){ref-type="fig"}). The patient experienced tinnitus in the right ear and transient headache on the left forehead approximately 5 h after Gd-DTPA injection. The latest follow-up was performed in 5 mon, and no vertigo attack was noted, but the tinnitus still existed.Fig. 6Perioperative audiograms demonstrating hearing changes. Improvements at higher frequencies were noted, but loss at the frequencies of 250 and 500 Hz in the right ear 1 month after operation (B) was noted compared with that before the operation (A). B type tympanogram indicating middle ear fluids on the right side (C).Fig. 6Fig. 7Audiogram and tympanogram 2 mon postoperation.Fig. 7Fig. 8Inner ear MRI of potent endolymphatic hydrops 4 mon after operation. Images were acquired using modified 3D-real inversion recovery sequence 24 h after targeted transtympanic injection of Gd-DTPA. The endolymphatic sacs (ES) were symmetric bilaterally (A). There were extreme cochlear endolymphatic hydrops (CEH) (B) in the right ear (R) and mild vestibular endolymphatic hydrops (VEH) on both sides (C). L: left ear.Fig. 8

4. Discussion {#sec4}
=============

The involvement of the immune response in this patient with MD was supported by the finding of novel rare coding variants in *PRF1*, *UNC13D*, *SLC29A3*, *ITCH*, and *JAK3* and the comorbid of hyperthyroidism suggesting autoimmune MD type 5. The regulation of the expression of the receptor Fn14 and the transcription factor NF-κB is mediating inflammation in the carrier of the non-coding risk allelic variant rs4947296 ([@bib14]). *PRF1* heterozygous mutations, such as c.1091T \> G, c.282C \> A/p.N94K, and c.1349C \> T/p.T450M, are associated with familial hemophagocytic lymphohistiocytosis type 2 ([@bib23]; [@bib29]). A compound heterozygous mutation in *UNC13D* gene could be detrimental in familial hemophagocytic lymphohistiocytosis ([@bib72]; [@bib75]). Hemophagocytic lymphohistiocytosis is an immune disorder caused by the uncontrolled activation of T lymphocytes and macrophages, which demonstrates a group of syndromes characterized by infiltration of multiple organs and reduction of hemocytes due to excessive generation of inflammatory cytokines. Autoinflammatory disease, such as adult-onset hemophagocytic lymphohistiocytosis, may also occur in adults and may be triggered by infection ([@bib1]; [@bib5]). The current patient exhibited elevated anti-β2GPI antibodies and reduced hemocytes in blood. Anti-β2GPI antibodies may trigger the TLR4-MyD88 signaling pathway or stimulate DNA sensors in the cytoplasm through binding to cell surface β2GPI and lead to activation of inflammatory signaling pathways and expression of tissue factor (TF) ([@bib66]). The patient was also diagnosed with hyperthyroidism and secondary hypothyroidism, which is suggestive of Graves' disease, a subtype of autoimmune thyroid disease ([@bib28]). However, antibodies against thyroglobulin protein, thyroid peroxidase, and thyroxine receptor were in normal range, indicating that an autoinflammatory rather than autoimmune reaction was involved in the thyroid disease of the current patient ([@bib35]). Heterozygous mutations in these 2 genes might have caused autoinflammation in the inner ear of the current patient. McDermot et al. proposed an autoinflammatory phenotype which results from impaired downregulation of membrane tumor necrosis factor receptor 1 (TNFR1) and diminished shedding of potentially antagonistic soluble receptor ([@bib38]). Six categories of autoinflammatory disease have been defined according to the molecular pathophysiology ([@bib36]). The present results indicate a novel autoinflammatory MD which might be distinguished from autoimmune MD type 5. In a previous report, the best predictors for clustering were autoimmune history, famial MD, migraine, and the onset of hearing loss, and type 5 MD is heterogeneous. Ninety-five patients remained unclassified because of incomplete clinical data ([@bib15]). A subset of MD patients with high basal levels of cytokines and negative autoantibodies was suggested as an autoinfammatory condition involving the inner ear ([@bib16]).

The *SLC29A3* gene encodes human equilibrative nucleoside transporter 3 (hENT3), a member of a largely conserved group of solute carrier transporters that is located in the endosome/lysosome and mitochondrial membrane. *SLC29A3* mRNA expression has also been detected in the inner ear of mouse embryo ([@bib45]). hENT3 regulates T cell homeostasis by coordinating lysosomal function with nucleoside availability ([@bib67]), and hENT3 spectrum disorder impairs nucleoside transport, protein localization, and stability ([@bib21]). The patients display symptoms such as cutaneous hyperpigmentation, hypertrichosis, cardiac abnormalities, hearing loss, hepatomegaly hypogonadism, and pigmented hypertrichotic dermatosis with insulin-dependent diabetes ([@bib21]). The E3 protein ubiquitin ligase *ITCH* gene encodes 854 amino acids with a relative molecular weight of 113 kDa. *ITCH* plays key roles in different cellular contexts given its functionally distinct substrates. *ITCH* targets are categorized in 2 main classes: transcription factors and growth factor receptors. Aberrant accumulation of several signaling proteins, such as the Jun family members and Notch, due to the loss of *ITCH* protein critically contributes to autoimmunity ([@bib40]; [@bib48]). *JAK3* mutation is associated with cytotoxic T lymphocyte antigen-4-dependent immune dysregulation syndrome ([@bib58]). The overall effects of above gene mutations might cause autoinflammation, autoimmunity, and even direct impairment in the inner ear; however, the biological effects of heterogenic mutations of the above genes require further investigation. The patient experienced her first autoinflammatory disease at 38 years old (hyperthyroidism in 1999). Her daughter does not have any associated diseases to date at the age of 31; however, she carries the reported gene mutations. It is possible that multiple pathways are involved in disease development, including genetic mutations and environmental impacts.

The vertigo was immediately relieved after operation. This excellent result might be attributed to the powerful anti-inflammatory effect of the novel high-dose steroids delivered to the surface of both the intact ES and incus. The surgery itself likely did not contribute to symptom relief given that the ES was symmetric bilaterally and EH existed 4 mon after operation without symptoms. It is possible that the endolymphatic pressure was reduced, attributed to inflammation inhibition. In addition, the Reissner\'s member remained in the extended position, which potentially resulted from a plasticity that was observed in an animal model ([@bib82]). At 1 mon after operation, hearing improvements greater than 2 kHz might be associated with anti-inflammation treatment. Worse hearing at 250 and 500 Hz may result from vibration during drilling of the temporal bone, in which the low frequencies are transmitted into the skull more efficiently compared with higher frequencies ([@bib62]; [@bib81]). Although the third window effect was suspected to contribute to low-tone air-bone gaps after endolymphatic sac surgery ([@bib25]), the conductive hearing loss in the present case seems to result from the fluids in the middle ear cavity after steroid delivery, which was indicated by the type B tympanogram ([Fig. 6](#fig6){ref-type="fig"}E). This hypothesis was supported by hearing recovery on 53 d postoperation. The improvements in hearing over all frequencies at 2-mon postoperation compared with before surgery suggested that the mechanism of hearing loss might be associated with impairment of the cell populations that are capable of regeneration, such as lateral wall structures, rather than hair cells. The elimination of tinnitus is possibly associated with the anti-inflammatory effect. The recurred tinnitus after Gd-DTPA injection might be associated to psychiatric reaction to the MRI study, which was suggested by the transient headache on the left forehead after Gd-DTPA injection. The patient told me that she worried about the last MRI study when she had no symptom appeared.

The fibrin glue-sealed gelatin sponge worked as a natural sustained-release vehicle. A previous study reported that a neurotrophin-3/fibroin-coated gelatin sponge scaffold generated sustainable cargo release up to 28 d ([@bib27]). One of the arms delivered steroids to the ES surface to modify the immune status of the ES. The more porous subepithelial capillary of ES due to inflammation facilitates the penetration of steroids throughout the ES layers after delivery onto the surface ([@bib17]). The excellent therapeutic effect of the present method may work through modifying macrophage polarizations in the inner ear, especially in the ES. Macrophages play critical roles in the immune reaction by differentiating into two subsets in response to environmental stimuli: classically (M1) or alternatively (M2) activated macrophages. M1 polarization facilitates proinflammatory function and efficient antigen presentation in macrophages. In contrast, M2 macrophages play anti-inflammatory and scavenger roles ([@bib8]; [@bib18]; [@bib39]; [@bib69]). Adoptive transfer of M2 macrophages successfully prevented type 1 diabetes and experimental colitis progression in mice, indicating the beneficial effects of M2 macrophages in controlling autoimmune diseases ([@bib19]; [@bib49]). High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia ([@bib13]). High-dose dexamethasone also induced lipopolysaccharide-stimulated rat alveolar macrophage apoptosis with downregulation of tumor necrosis factor-α and interleukin (IL)-12 and upregulation of IL-10 and transforming growth factor-β ([@bib73]). The human sac is endowed with a variable number of leucocytes, and there is a continuous recirculation of immunocompetent cells in this area of the inner ear ([@bib50]).

The second arm delivers dexamethasone to the vestibule and cochlea to further modify the immune status in the inner ear. In an MRI study, attic delivery of gadolinium-chelate diffused along the ossicular chain towards the oval window and then efficiently entered the vestibule and cochlea in rats ([@bib77]; [@bib79]). Although the histology of the human oval window may differ from that of rats, the surface chemistry of the ossicular chain should be similar between human and rats. The efficient passage of gadolinium-chelate through the human oval window has been demonstrated in our previous study using MRI ([@bib57]). Therefore, sufficient dexamethasone might be supplied to the vestibule and cochlea via the second arm of the "L"-shaped gelatin sponge. The cochlea is active in inducing the immune reaction and inflammation. The lateral wall structures, including stria vascularis and spiral ligament, have been reported as the primary site harboring macrophages in the inner ear of human and mouse ([@bib47]; [@bib74]). Nonsensory supporting cells of Corti\'s organ play an irreplaceable role in immune surveillance of the inner ear ([@bib26]; [@bib53]; [@bib61]). In response to lipopolysaccharide, spiral ligament fibrocytes exhibited TLR2-dependent nuclear factor-κB signaling activation and monocyte chemoattractant proteins-1 upregulation, resulting in monocyte migration and consequential infiltration ([@bib44]; [@bib68]). Our previous study demonstrated that ubiquitin-editing protein A20 and RING finger protein11 played roles in maintaining cochlear homeostasis via negative regulation of the expression of inflammatory cytokines ([@bib12]). Dexamethasone inhibits tumor necrosis factor-α-induced cytokine secretion from spiral ligament fibrocytes ([@bib31]). Glucocorticoid receptors were broadly expressed in the cochlear cell populations and respond to dexamethasone in a manner suggestive of dose-induced translocation ([@bib22]).

Some recognized limitations of the present report should be noted. The clustering and molecular pathophysiology of MD associated with autoinflammation is unknown. There was only one case in the observation, and the follow up period was short (5 mon). MD is often a chronic condition, and recurrence within months is possible. In general, a randomized controlled trial (RCT) including a placebo treatment provides the strongest evidence. However, it is unpractical to performed an RCT study in China, especially for surgery. Given that the symptom attacks did not recur despite the lack of additional steroid supply indicates an unknown mechanism of macrophage plasticity within the inner ear. Therefore, a long-term follow-up and large sample investigation is necessary to draw final conclusions regarding this novel therapy in the future.

5. Conclusions {#sec5}
==============

Autoinflammation in the refractory MD case was indicated by the genotypes of novel heterozygous mutations of PRF1, UNC13D, SLC29A3, ITCH, and JAK3; blood test characteristics; and previous diagnoses of hyperthyroidism and secondary hypothyroidism. It is necessary to complete the clustering and molecular pathophysiology of MD in the future. The preliminary results suggested that the novel therapy that delivers steroids to the surface of the intact endolymphatic sac and incus effectively relieves vertigo and tinnitus and improves hearing function of refractory MD, opening a new avenue of treatment in the clinic.
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[^1]: 1000G: 1000 genome; gnomAD-exomeEAS: gnomAD-exome EAS: the population frequencies of exome variant data in the eastern Asian descent provided by Genome Aggregation Database (gnomAD); het: heterogenous; Polyphen2: Polymorphism Phenotyping v2; SIFT: sorting intolerant from tolerant; UA: data unavailable.

[^2]: \*These variants were not reported in Meniere\'s disease.
